Team:Brown/Project

From 2009.igem.org

(Difference between revisions)
Line 3: Line 3:
== Project Abstract==
== Project Abstract==
-
The 2009 Brown iGEM Team aims to treat allergic rhinitis by engineering "Staphylococcus epidermidis" to secrete a histamine binding protein in response to elevated histamine concentrations during an allergic attack. The histamine-binding protein, rEV131, has been cloned from a species of tick, "Rhipicephalus appendiculatus". rEV131 binds histamine with an extreme high affinity, and normally functions to prevent the inflammatory response while the tick sucks blood. We are transforming the gene for rEV131 into an endogenous nasal flora, "S. epidermidis". rEV131 will have a secretion tag specific for S. epidermidis.
+
 
-
Additionally, to synchronize rEV131 production with elevation of histamine, we are engineering a novel histamine receptor, via mutagenic PCR. We are mutating periplasmic receptors normally linked to gene transcription. The eventual goal is to link this histamine-responsive receptor to activation of an operon that promotes transcription of rEV131.
+
Brown University’s 2009 iGEM Team presents an exciting new approach to treating nasal allergies through Allergene: a synthetically engineered, self-regulating drug factory in the nose. This revolutionary new product provides a much-needed alternative to current antihistamines by directly sequestering the histamine released in an allergic response. Such a method effectively eliminates both the symptoms of an allergy and the negative side effects that plague their currently available clinical treatments.
-
Although "S. epidermidis" is a non-pathogenic specimen, additional safety precautions are being taken to control over-proliferation. When "S. epidermidis" reaches a certain population threshold, it begins to produce hazardous biofilms. We have cloned this population sensor, however, and placed its promoter over a DNA gyrase poison, cuing its "suicide" when populations have reached a dangerous level.
+
Rather than presenting a system that passively sequesters histamine; however, Allergene goes one step further to providing patients with much-needed allergy relief. Activation of the product only occurs in the explicit event of an actual allergic response. Through a remarkable ability to detect subtle changes in extra-cellular histamine, Allergene’s unique histamine sequestering system is engineered to function only when histamine levels are markedly high. This efficiently timed system is therefore completely self-regulating.
 +
Allergene is introduced to its host patients by capitalizing on the endogenous existence of bacterium Staphylococcus epidermidis in human nasal flora. This naturally present organism is the perfect vehicle for delivery; its rapid production and secretion of Allergene’s genetic constructs effectively implement the system’s histamine sensing and sequestering capabilities in human hosts. In order to eliminate any safety concerns associated with the utilization of S. epidermidis in human hosts, special care has additionally been taken to engineer the product’s accessory kill switch mechanism. Named the “Quorum Sensor”, this thoughtful, additional feature prompts Allergene’s swift response in the unfavorable event of over-cell-proliferation.

Revision as of 04:30, 20 October 2009


Project Abstract

Brown University’s 2009 iGEM Team presents an exciting new approach to treating nasal allergies through Allergene: a synthetically engineered, self-regulating drug factory in the nose. This revolutionary new product provides a much-needed alternative to current antihistamines by directly sequestering the histamine released in an allergic response. Such a method effectively eliminates both the symptoms of an allergy and the negative side effects that plague their currently available clinical treatments. Rather than presenting a system that passively sequesters histamine; however, Allergene goes one step further to providing patients with much-needed allergy relief. Activation of the product only occurs in the explicit event of an actual allergic response. Through a remarkable ability to detect subtle changes in extra-cellular histamine, Allergene’s unique histamine sequestering system is engineered to function only when histamine levels are markedly high. This efficiently timed system is therefore completely self-regulating. Allergene is introduced to its host patients by capitalizing on the endogenous existence of bacterium Staphylococcus epidermidis in human nasal flora. This naturally present organism is the perfect vehicle for delivery; its rapid production and secretion of Allergene’s genetic constructs effectively implement the system’s histamine sensing and sequestering capabilities in human hosts. In order to eliminate any safety concerns associated with the utilization of S. epidermidis in human hosts, special care has additionally been taken to engineer the product’s accessory kill switch mechanism. Named the “Quorum Sensor”, this thoughtful, additional feature prompts Allergene’s swift response in the unfavorable event of over-cell-proliferation.